Shorter infusions for fabry disease: a step toward less time in the chair
NCT ID NCT06019728
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tested whether increasing the infusion rate of Fabrazyme, a lifelong enzyme replacement therapy for Fabry disease, is safe and tolerable. Eight participants who had been on Fabrazyme for at least 3 months without infusion reactions received faster infusions with less fluid. The goal was to see if treatment time could be shortened without causing side effects, potentially reducing the burden of regular infusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University School of Medicine Site Number : 1005
Atlanta, Georgia, 30322-1007, United States
-
Infusion Associates Site Number : 1001
Grand Rapids, Michigan, 49525, United States
-
Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002
Fairfax, Virginia, 22030, United States
-
Metropolitan Hospital Center Site Number : 1004
New York, New York, 10021, United States
-
UCLA Medical Center Site Number : 1003
Santa Monica, California, 90404, United States
Conditions
Explore the condition pages connected to this study.